Patritumab

Synonyms: 帕曲妥单抗; AMG-888; U3-1287
Patritumab 是一种靶向 ERBB3 的中和性单克隆抗体,与 Cetuximab (MS-F27523) 具有协同作用,可有效抑制 EGFR、HER2、HER3、ERK 和 AKT 的磷酸化,诱导细胞凋亡 (apoptosis),并抑制胰腺癌、非小细胞肺癌和结直肠癌异种移植物的肿瘤生长。
产品编号: MS-G79979 纯度: 99.28% CAS No.: 1262787-83-6
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Patritumab 是一种靶向 ERBB3 的中和性单克隆抗体,与 Cetuximab (MS-F27523) 具有协同作用,可有效抑制 EGFR、HER2、HER3、ERK 和 AKT 的磷酸化,诱导细胞凋亡 (apoptosis),并抑制胰腺癌、非小细胞肺癌和结直肠癌异种移植物的肿瘤生长。

生物实验数据

生物活性 Patritumab is a neutralizing monoclonal antibody targeting ERBB3 that acts synergistically with Cetuximab (MS-F27523) to effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK, and AKT, induce apoptosis, and suppress tumor growth in pancreatic, non-small cell lung, and colorectal cancer xenografts.
IC50 & Target

ERBB3/HER3

体外研究
(In Vitro)

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.

Western Blot Analysis

Cell Line: DiFi-HRG cells
Concentration: 10 μg/mL
Incubation Time: 6 hours
Result: Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
体内研究
(In Vivo)

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.

Animal Model: Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage: 1 mg/body
Administration: Intraperitoneal injection; twice a week for 4 weeks
Result: Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.
Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT02980341Daiichi Sankyo Co., Ltd.|Daiichi Sankyo|Merck Sharp & Dohme LLC
Metastatic Breast Cancer
2016-11-28PHASE1|PHASE2
NCT06469944Merck Sharp & Dohme LLC
Gastroesophageal Junction|Gastroesophageal Adenocarcinoma|Esophageal Neoplasms|Esophageal Cancer
2024-09-20PHASE1|PHASE2
NCT02633800Daiichi Sankyo
Head and Neck Neoplasms
2015-12-22PHASE2
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 1262787-83-6
别名 帕曲妥单抗; AMG-888; U3-1287

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础